Abstract 535P
Background
Copy number alterations (CNAs) are common consequences of genome instability in lung cancer. Focal amplifications in NKX2-1 copy number (CN) have been frequently observed in non-small cell lung cancer (NSCLC). However, beyond CN gain, little is known about the complete landscape of NKX2-1 CNAs, their clinical significance, and their therapeutic implications in NSCLC.
Methods
Correlations of NKX2-1 expression with EGFR driver mutations and PD-L1 co-expression were studied using immunohistochemistry and PCR from tumors of recruited Filipino patients (n=45). Clinical features of NSCLC with NKX2-1 CNAs were resolved at the tumor and clonal levels using the molecular profiles of LUAD and LUSC participants from TCGA (n=1,130), and deconvoluted single-cell RNA-seq data from Bivona project (n=1,654), respectively.
Results
NKX2-1 expression and CN variations correlated significantly (r= 0.264; p<0.001). However, NKX2-1 CNAs exert a stronger influence on the combined EGFR and PD-L1 status of NSCLC tumors (p<0.05) than expression (p>0.05). NKX2-1 CN gain was prognostic of favorable survival (p=0.018), whereas, NKX2-1 CN loss prognosed worse survival (p=0.041). Mutational architecture in Y-chromosome differentiates the two prognostic groups. There were 19,941 synonymous mutations and 1,408 genome-wide CN perturbations associated with NKX2-1 CNAs. Tumors with NKX2-1 CN gain had higher B cell (p<0.001) and total T cell estimates (p=0.003). NKX2-1 CN loss was associated with colder tumors due to higher M2 macrophage infiltrates (p=0.011) and higher expression of immune checkpoint proteins, CD274 (p=0.025), VTCN1 (p<0.001), and LGALS9 (p=0.002). Lymphocyte marker signature in CN gain was prognostic of longer disease-free survival (p=0.005).
Conclusions
NKX2-1 CNAs are associated with tumors that exhibit clinically diverse characteristics, and with unique oncogenic, immunologic, and prognostic signatures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Science and Technology - Philippine Council for Health Research and Development.
Funding
Department of Science and Technology - Philippine Council on Health Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract